AI Article Synopsis
- The study analyzed the results of Low-Dose Computed Tomography (LDCT) screenings in a population from West China Hospital to compare eligible and ineligible candidates based on lung cancer screening guidelines.
- Findings showed that 64.13% of participants were ineligible for screening, with 39.04% of them testing positive, leading to a surgical lung biopsy rate of 4.17%.
- Notably, ineligible candidates had a higher false-positive rate and a significant proportion of lung cancer cases, particularly lung adenocarcinoma, among current smokers, especially in males.
Article Abstract
To compare the LDCT screening results between eligible and ineligible screening candidates in preventive health check-ups population. Using a real-world LDCT screening results among people who took yearly health check-up in health management center of West China Hospital between 2006 and 2017. Objects were classified according to the China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2018 version) eligibility criteria. Descriptive analysis were performed between eligible and ineligible screening candidates. The proportion of ineligible screening candidates was 64.13% (10,259), and among them there were 4005 (39.04%) subjects with positive screenings, 80 cases had a surgical lung biopsy. Pathology results from lung biopsy revealed 154 cancers (true-positive) and 26 benign results (false-positive), the surgical false-positive biopsy rate was 4.17%, and ineligible group (7.69%) was higher than eligible group (2.47%), P < 0.05. Further, in ineligible screening candidates, the proportion of current smokers was higher among males compared to females (53.85% vs. 4.88%, P < 0.05). Of the 69 lung cancer patients detected in ineligible screening candidates, lung adenocarcinoma accounts for a high proportion of lung cancers both in male (75.00%) and female (85.00%). The proportion of ineligible screening candidates and the surgical false-positive biopsy rate in ineligible candidates were both high in health check-ups population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10902338 | PMC |
| http://dx.doi.org/10.1038/s41598-024-55475-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals.
Lancet Psychiatry
January 2025
Developmental Evidence synthesis, Prediction, Implementation lab, Centre for Innovation in Mental Health, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; Hampshire and Isle of Wight NHS Foundation Trust, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York City, NY, USA; DiMePRe-J-Department of Precision and Regenerative Medicine-Jonic Area, University of Bari Aldo Moro, Bari, Italy.
Background: Randomised controlled trials (RCTs) evaluating ADHD medications often use strict eligibility criteria, potentially limiting generalisability to patients in real-world clinical settings. We aimed to identify the proportion of individuals with ADHD who would be ineligible for medication RCTs and evaluate differences in treatment patterns and clinical and functional outcomes between RCT-eligible and RCT-ineligible individuals.
Methods: We used multiple Swedish national registries to identify individuals with ADHD, aged at least 4 years at the age of diagnosis, initiating pharmacological treatment between Jan 1, 2007, and Dec 31, 2019, with follow-up up to Dec 31, 2020.
Biomarkers.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Individuals from diverse racial and ethnic groups are severely underrepresented in AD trials in part due to disproportionate biomarker ineligibility. Evidence from recent studies support plasma phosphorylated tau (P-tau217) as an early marker for brain Aβ pathology and a reliable marker in predicting elevated brain amyloid PET in cognitively unimpaired adults. We examined the relationship between P-tau217 and florbetapir PET standard uptake value ratios (SUVR) by self-reported racial and ethnic groups in preclinical AD studies.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
University of California, San Francisco, San Francisco, CA, USA.
Background: Nearly 1 in 3 older adults are living with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), which places them at increased risk of developing Alzheimer's disease or related dementias (ADRD). Behavioral interventions can improve cognitive function and reduce dementia risk factors, but most are in-person and time-intensive. We are conducting a randomized, controlled trial to assess the impact of 12- and 24-week online interventions on cognitive function and dementia risk.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Alzheimer's disease (AD) disproportionately affects minoritized populations, who are consistently underrepresented in clinical trials. We aimed to recruit underrepresented adults aged 55-80 to an ongoing preclinical AD trial.
Method: A community-based strategy was used to recruit Filipino, Hispanic/Latino, and Korean adults into the AHEAD study, a preclinical AD trial testing the anti-amyloid treatment lecanemab, at the University of California, Irvine.
Biomarkers.
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Background: The increasing dementia prevalence and potential introduction of disease-modifying therapies (DMTs) highlight the need for efficient diagnostic pathways. Clear recommendations to guide the choice of diagnostic tests are lacking and may vary depending on different clinical scenarios. We used a data-driven approach to identify efficient and effective stepwise diagnostic testing for three clinical scenarios: 1) syndrome diagnosis, 2) etiological diagnosis, 3) potential eligibility for DMT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!